I’m sorry, but the excerpt you provided only includes the timing of Coloplast A/S’s upcoming conference call and the fact that a presentation will be posted on its website. It does not contain any figures for the nine‑month (9M) 2024/25 earnings, nor does it give any information about analyst expectations or consensus forecasts for those results.
To answer your question—how the 9M 2024/25 earnings compare to analyst expectations and consensus forecasts—I would need the actual earnings numbers (e.g., revenue, profit, earnings per share) and the corresponding analyst estimates. If you can share those details (or a link to the full earnings release), I’ll be able to provide a comprehensive comparison.
Other Questions About This News
What is the current free cash flow generation and its impact on planned share buy‑backs or capital allocation?
Are there any upcoming catalysts or events (e.g., regulatory approvals, M&A activity, conferences) that could influence the stock price in the near term?
Are there any changes to the dividend policy or payout ratio following the interim results?
What are the expectations for the upcoming FY 2025/26 guidance, especially regarding the product pipeline and upcoming product launches?
Did management comment on any macro‑economic or regulatory risks that could affect future performance?
Which Business Units (e.g., Colostomy, Urology, Wound Care) drove the performance, and were there any notable segment trends?
What is the outlook for full‑year 2024/25 earnings and guidance – any revisions to revenue, EBITDA, or EPS forecasts?
How does the current valuation (P/E, EV/EBITDA) compare to key competitors in the medical device sector after this release?
How did currency fluctuations (euro, US $) affect the reported results, and what hedging strategies are in place?
What is the expected impact of the 9M results on the stock’s technical indicators (e.g., support/resistance levels) in the short‑term?
What were the revenue growth rates and margins for the 9 months, and how do they compare year‑over‑year and to the prior quarter?